JPRN-jRCT2080220266未知3 期
A Randomised, Double-Blind, Study Comparing ARIMIDEX With NOLVADEX as Neo-Adjuvant and Adjuvant Treatment in Post-Menopausal Women With Large Operable (T2 (=3cm), T3, N0-2, M0) or Potentially-Operable, Locally Advanced (T4b, N0-2, M0), ER+ and/or PR+ Breast Cancer
适应症
试验速览
- 阶段
- 3 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 60age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •Ages Eligible for Study: 60 Years and above, Genders Eligible for Study: Female
- •Inclusion Criteria:
- •- Operable or potentially operable breast cancer
- •- Invasive breast cancer proven to be hormone-sensitive (ER+/PR+)
- •- Patients who might benefit from endocrine treatment prior to surgery
- •- Postmenopausal
- •- Signed written informed consent
排除标准
- •- Inoperable breast cancer
- •- Patient unwilling to undergo surgery
- •- Any reason why the patient may not be able to conform to study requirements
- •- Any previous treatment for breast cancer
- •- Previous Tamoxifen use as a part of breast cancer prevention trials
- •- Not willing to stop taking drugs that affect sex-hormones such as HRT
- •- Previous history of breast cancer
- •- Previous history of invasive malignancy within the last 10 years
- •- Any other severe disease that may prevent surgery, place the patient at risk, or influence the study results
- •- Treatment with an experimental drug within the last 3 months
- •- Risk of transmitting HIV, Hepatitis B or C
研究者
相似试验
已完成
不适用
A randomised double-blind trial comparing arimidex alone with nolvadex alone with arimidex and nolvadex in combination, as adjuvant treatment in post-menopausal women with breast cancerCancerBreast cancerISRCTN18233230AstraZeneca Clinical Research Group (UK)
已完成
3 期
ATAC - Arimidex, Tamoxifen, Alone or in CombinatioCancer - BreastBreast CancerACTRN12606000527561AstraZeneca (formerly known as Zeneca, formerly known as ICI)6,000
进行中（未招募）
不适用
A RANDOMISED, DOUBLE BLIND STUDY TO COMPARE THE ANALGESIC EFFICACY AND SAFETY PROFILES OF MORPHINE-6-GLUCURONIDE AND MORPHINE SULPHATE, GIVEN AS A LOADING DOSE FOLLOWED BY PATIENT-CONTROLLED ANALGESIA (PCA), IN PATIENTS SUFFERING MODERATE TO SEVERE POST-OPERATIVE PAIN REQUIRING PCA FOR AT LEAST 24 HOURS - N/AEUCTR2005-001690-99-CZCeNeS Ltd
进行中（未招募）
1 期
A RANDOMISED, DOUBLE BLIND STUDY TO COMPARE THE ANALGESIC EFFICACY AND SAFETY PROFILES OF MORPHINE-6-GLUCURONIDE AND MORPHINE SULPHATE, GIVEN AS A LOADING DOSE FOLLOWED BY PATIENT-CONTROLLED ANALGESIA (PCA), IN PATIENTS SUFFERING MODERATE TO SEVERE POST-OPERATIVE PAIN REQUIRING PCA FOR AT LEAST 24 HOURS - N/AEUCTR2005-001690-99-GBCeNeS Ltd480
进行中（未招募）
不适用
A RANDOMISED, DOUBLE BLIND STUDY TO COMPARE THE ANALGESIC EFFICACY AND SAFETY PROFILES OF MORPHINE-6-GLUCURONIDE AND MORPHINE SULPHATE, GIVEN AS A LOADING DOSE FOLLOWED BY PATIENT-CONTROLLED ANALGESIA (PCA), IN PATIENTS SUFFERING MODERATE TO SEVERE POST-OPERATIVE PAIN REQUIRING PCA FOR AT LEAST 24 HOURS - N/AEUCTR2005-001690-99-DECeNeS Ltd